EW Share Price Performance
US$85.96
8.44 (10.89%)
11.3% undervalued intrinsic discount
US$96.92
Fair Value
Price US$85.96
AnalystConsensusTarget US$96.92
Fair ValueUS$96.92
Share Pricen/a
Narrative Update • Jun 03
Edwards Lifesciences Corporation Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 69 Fair Values set on narratives written by author
EW Community Narratives
AN
Fair Value
·Fair Value US$96.92 11.3% undervalued intrinsic discount
Durability Data And Real-World Evidence Will Shape Risk And Opportunity Ahead
0users have liked this narrative
0users have commented on this narrative
27users have followed this narrative
Durability Data And Real-World Evidence Will Shape Risk And Opportunity Ahead
Edwards Lifesciences is betting on new heart valve treatments to reach more patients, including earlier-stage cases, while pushing into new areas that few rivals can match. The upside hinges on smooth approvals and rollout, but tariffs, acquisition costs, and tougher competition abroad could squeeze profits if plans slip.Read more
AN
US$96.92
11.3% undervalued intrinsic discount
Fair Value
Revenue
9.63% p.a.
Profit Margin
26.02%
Future PE
30.3x
Price in 2029
US$120.58
Trending Discussion
Recently Updated Narratives
AN
EW: TAVR Share Gains And New CFO Will Shape Balanced 2026 Outlook
Fair Value: US$96.92 11.3% undervalued intrinsic discount
27 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Edwards Lifesciences Corporation Key Details
About EW
- Founded
- 1958
- Employees
- 16000
- CEO
- WebsiteView website
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
